At a glance
CDMO growth, 2026
Exhibit 1CDMO growth, latest quarter
Revenue growth year on year
The category on a page
Exhibit 2Where contract manufacturing sits
Profit impact against supply risk, R&D subcategories
Exhibit 4Samsung Biologics quarterly revenue
KRW trillion
Typical savings vs single-source renewal
Price, minimum volumes and batch failure terms
Value levers
In order of value.
Reserve slots with take-or-pay bands, not fixed volumes.
Dual source critical products, ideally in a different country.
Agree who pays Section 232 duty and when prices reset.
Supplier bears cost of failed batches it causes.
Pass through only indexed inputs; fix conversion costs.
Own process data; agree transfer support and cost.
How to buy it
KPIs to track
For the monthly review
Where most buyers are, and what good looks like
| Most buyers today | Best practice | ||
|---|---|---|---|
| Sourcing | Single site | → | Dual qualified sites |
| Capacity | Order when needed | → | Rolling 3-year reservations |
| Pricing | Fixed price list | → | Indexed inputs, fixed conversion |
| Risk | Annual audit | → | Geopolitical and tariff mapping |
| Exit | Not planned | → | Tech-transfer package agreed |
What AI changes
More in the AI disruption tab.
Full written analysis
Written live for Contract manufacturing (CDMO) and your region, grounded on the figures above. Public data only.
Written live for this category and region when the page opens in a browser.
Negotiation playbook
Negotiation playbook
Capacity is tight and CDMOs are growing double digits. Your leverage is long-term volume, the product's lifetime value, and a credible second source.
Pick the right commercial model
| Capacity reservation with creditsUsual best | Fee credited against orders; flexible volumes. |
| Price per batch | Simple; check what is included. |
| Cost-plus with open book | Transparent; needs audit rights. |
| Take-or-pay | Lower price, volume risk on you. |
Questions to ask suppliers
- Capacity
How many batches will you reserve for us each year to 2029, and how much can we move up or down without penalty?
Good answer: reserved slots with flexibility. - Batch failure
If a batch fails because of your process, will you replace it and cover the materials we supplied?
Good answer: supplier bears cost. - Tariffs
Who pays US Section 232 duty on our product, and will you share it if rates change?
Good answer: shared or absorbed. - Raw materials
Which inputs will you index, to which published index, and is conversion cost fixed?
Good answer: index, not ad hoc. - Second source
Will you support transfer of the process to a second site, at what cost and how fast?
Good answer: transfer support. - Geopolitics
Do you use any subcontractors or sites in China, and how would BIOSECURE affect them?
Good answer: subcontractors disclosed.
Your leverage
- Lifetime product volume
- Second qualified site
- Bundling development and commercial
- Timing before capacity fills
Watch out for
- Minimum volumes you can't use
- Unindexed price rises
- Process ownership lost to the CDMO
- Hidden China subcontracting
AI disruption
Tailwinds for buyers
- Process modelling cuts development experiments.
- Digital twins lift yields.
- AI batch record review speeds release.
- Predictive maintenance reduces downtime.
- Better demand forecasts reduce idle capacity.
- AI deviation analysis.
Headwinds for buyers
- Capacity shortage outweighs efficiency gains.
- Validation of AI in GMP is slow.
- Data ownership of process models.
- Cyber risk in connected plants.
- Supplier keeps efficiency gains.
- Regulators move cautiously.
How to capture it
Ask for yield and cycle-time gains to be shared through annual price reviews.
Who is changing the market
- Completed transformation into a pure-play CDMO in 2026
- Raised mid-term margin and growth ambitions
- Plant 5 ramp-up and a US site in Rockville
- Expanding into peptides through a planned acquisition
- Custom synthesis now about 60% of sales
- Peptide and backward integration lower cost
Risk radar
Risk radar
Exposure by dimension, 0-100, Global
Risk heat map
Impact against likelihood; numbers match the register below
- BIOSECURE restrictions
- Capacity shortage
- Quality failures
- Labour disruption
Risk register
WuXi AppTec added to the Pentagon 1260H list.
Leading CDMOs at or near full utilisation.
One failed audit can stop supply.
Samsung Biologics margin hit by a strike.
Market pulse
What the biggest suppliers are reporting
From their latest results and investor material.
Q3 2026 update (14 Oct). Now a pure-play CDMO; CORE EBITDA margin 33-34%; mid-term ambitions raised.
Q3 2026. KRW 1.49tn; operating margin fell to 42.9% after a May strike; 2026 growth guide raised to 20%; Rockville (US) site now contributing.
Q3 2026. 2026 guide raised to RMB 61-61.9bn; backlog RMB 76.7bn; OMB list of 'companies of concern' due by 18 Dec.
Q2 FY27. Rs 3,676 cr; custom synthesis +54% (Goldman); about 90% exported, Europe and North America about 75%.
Q2 FY27. CDMO revenue Rs 1,424 cr; FY27 group growth guide raised to 19-20%.
Q2 FY27. +13% vs Q1; EBITDA margin 18% vs 22% a year ago; first deal at its US Bayview biologics site; FY27 revenue to fall single digits.
9M 2026. Sales EUR 2.74bn; Stedim paid EUR 28m tariff compensation to customers; full-year guide confirmed.
Latest developments
Dated, newest first. Checked 16 Nov 2026.
9M revenue +39%; OMB list due 18 Dec.
So what: Decide your China exposure plan before the list lands.
Fierce Pharma →Guide raised to 20%; strike hit batches.
So what: Capacity tight; ask for continuity terms.
Korea Times →Now a pure-play CDMO.
So what: Expect firm pricing; lock long-term slots.
Manufacturing Chemist →Profit +64%; ~90% exported.
So what: Indian capacity filling; commit volumes early.
Divi's Q2 FY27 results (NSE filing) →What this means for your next negotiation
- Capacity is tightening; reserve 2027-2029 slots with flexible bands.
- Map every product's origin for US tariffs and BIOSECURE before December.
- Indian CDMOs are the main non-China alternative and are filling fast.
Signals to watch next quarter
Defines which Chinese suppliers are restricted.
Announced, not yet law.
Signals capacity and pricing.
Sources
- Lonza Q3 2026 update · 14 Oct 2026
- Samsung Biologics Q3 2026 · 21 Oct 2026
- WuXi AppTec 9M 2026 (Fierce Pharma) · Oct 2026
- Divi's Q2 FY27 · Nov 2026
- Piramal Pharma Q2 FY27 · 30 Oct 2026
- Section 232 pharmaceutical tariffs (JD Supra) · Apr 2026
- Sartorius 9M 2026 · 22 Oct 2026
Figures checked 16 Nov 2026. Tags: Official = published by the source; Derived = calculated from published figures; Judgement = The Procurement Lens view.